Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O W Akkerman

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 23, 2021
Assessment of TB treatment on patient well-beingM P Schultink, H A M Kerstjens, L Ter Beek, et al.
Plos One|August 5, 2022
Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteersY A de Reus, P Hagedoorn, M G G Sturkenboom, et al.
Antimicrobial Agents and Chemotherapy|April 13, 2016
Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of TuberculosisN Alsaad, J A Dijkstra, O W Akkerman, et al.
International Journal of Antimicrobial Agents|August 1, 2015
Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosisJ A Dijkstra, R van Altena, O W Akkerman, et al.
Expert Opinion on Drug Safety|May 25, 2021
The long-term safety of chronic azithromycin use in adult patients with cystic fibrosis, evaluating biomarkers for renal function, hepatic function and electrical properties of the heartA M Akkerman-Nijland, J E Möhlmann, O W Akkerman, et al.
Plos One|September 24, 2020
Colistin dry powder inhalation with the Twincer™: An effective and more patient friendly alternative to nebulizationA M Akkerman-Nijland, F Grasmeijer, H A M Kerstjens, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2018
<i>In Vitro</i> Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and CapreomycinJ A Dijkstra, T van der Laan, O W Akkerman, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2018
Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis PatientsM A Zuur, S Ghimire, M S Bolhuis, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2017
Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant TuberculosisS P van Rijn, M A Zuur, R van Altena, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 30, 2025
Artificial intelligence for TB education and counselling: a modified Delphi consensusJ N Ngiam, M C Y Koh, L D'Ambrosio, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 23, 2021
Assessment of TB treatment on patient well-beingM P Schultink, H A M Kerstjens, L Ter Beek, et al.
Plos One|August 5, 2022
Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteersY A de Reus, P Hagedoorn, M G G Sturkenboom, et al.
Antimicrobial Agents and Chemotherapy|April 13, 2016
Pharmacokinetic Evaluation of Sulfamethoxazole at 800 Milligrams Once Daily in the Treatment of TuberculosisN Alsaad, J A Dijkstra, O W Akkerman, et al.
International Journal of Antimicrobial Agents|August 1, 2015
Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosisJ A Dijkstra, R van Altena, O W Akkerman, et al.
Expert Opinion on Drug Safety|May 25, 2021
The long-term safety of chronic azithromycin use in adult patients with cystic fibrosis, evaluating biomarkers for renal function, hepatic function and electrical properties of the heartA M Akkerman-Nijland, J E Möhlmann, O W Akkerman, et al.
Plos One|September 24, 2020
Colistin dry powder inhalation with the Twincer™: An effective and more patient friendly alternative to nebulizationA M Akkerman-Nijland, F Grasmeijer, H A M Kerstjens, et al.
Antimicrobial Agents and Chemotherapy|January 10, 2018
<i>In Vitro</i> Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and CapreomycinJ A Dijkstra, T van der Laan, O W Akkerman, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2018
Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis PatientsM A Zuur, S Ghimire, M S Bolhuis, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2017
Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant TuberculosisS P van Rijn, M A Zuur, R van Altena, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 30, 2025
Artificial intelligence for TB education and counselling: a modified Delphi consensusJ N Ngiam, M C Y Koh, L D'Ambrosio, et al.
Pageof 4